Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00306618

Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma

Recurrent Glioblastoma Multiforme Clinical Trial

Official title:
A Single-Center, Open-Label, Phase II, Safety, Pharmacokinetic and Efficacy of Panzem Nanocrystal Colloidal Dispersion Administered Orally to Patients With Recurrent Glioblastoma Multiforme

Clinical Trial Summary

This single-center, open-label, phase 2 study will evaluate the anti-tumor activity, as well as the safety and pharmacokinetics, of Panzem (2-methoxyestradiol, 2ME2) Nanocrystal Colloidal Dispersion (NCD) administered in patients with recurrent glioblastoma multiforme (GBM)

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00306618
Study type Interventional
Source CASI Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 2
Start date January 2006
Completion date December 2008
View Details
See also
  Status Clinical Trial Phase
Completed NCT00597493 - Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM Phase 2
Completed NCT00379470 - Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) Phase 3
Recruiting NCT01737346 - Procarbazine and Lomustine in Recurrent Glioblastoma Phase 2
Active, not recruiting NCT01464177 - Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme Phase 2
Active, not recruiting NCT00562419 - CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan Phase 2
Completed NCT00071539 - Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors Phase 2
Active, not recruiting NCT02062827 - Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma Phase 1
Completed NCT00509301 - Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme Phase 1
Recruiting NCT05868083 - The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma Phase 1
Completed NCT01576666 - Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Phase 1
Completed NCT01738646 - Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients Phase 2
Completed NCT01934361 - Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme Phase 1
Terminated NCT04915404 - Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) Phase 1/Phase 2
Terminated NCT01756729 - Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Phase 4
Completed NCT00747253 - Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors Phase 1
Completed NCT00883298 - Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme Phase 2
Completed NCT00481455 - Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM) Phase 2
Recruiting NCT03423628 - A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer Phase 1
Recruiting NCT04689087 - A Prospective, Open-label, Single-arm Clinical Study N/A